Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2
The Lancet Microbe · 2025-11 · 6 (11) · 101165
DOI: 10.1016/j.lanmic.2025.101165 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Lancet Microbe, 2025-11. Verfasst von Lu Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HORIZON EUROPE Health, European Social Fund for Germany, Lower Saxony State Ministry of Science and Culture.
Abstract (Originalsprache)
The COVID-19 pandemic and the ensuing endemic have been characterised by the continuous emergence of novel SARS-CoV-2 variants, each showing augmented antibody evasion due to mutations in the viral spike (S) protein. These new variants usually harbour a few S protein mutations, conferring a modest growth advantage within the population. However, a quantum leap of SARS-CoV-2 evolution was observed on two occasions. The first occurred at the end of 2021, when the highly mutated omicron variant (B.1.1.529) became dominant, showing unprecedented antibody evasion.
Autor:innen und Institutionen
- Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany.
- Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
- Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany; German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Hannover, Germany.
- Department for Paediatric Pneumology, Hannover Medical School, Hannover, Germany; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany; German Centre for Lung Research (DZL), partner si…
- Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
- Division of Molecular Immunology, Department of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
Förderung
- HORIZON EUROPE Health
- European Social Fund for Germany
- Lower Saxony State Ministry of Science and Culture
- Bavarian Research Foundation
- German Research Foundation
- Federal Ministry of Education and Research Bonn Office
Zitieren
APA
Zhang, L., Kempf, A., Nehlmeier, I., Chen, N., Stankov, M. V., Happle, C., Dopfer-Jablonka, A., Behrens, G. M. N., Schulz, S. R., Jäck, H. M., Pöhlmann, S., & Hoffmann, M. (2025). Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2. The Lancet Microbe, 6(11), 101165. https://doi.org/10.1016/j.lanmic.2025.101165
Vancouver
Zhang L, Kempf A, Nehlmeier I, Chen N, Stankov MV, Happle C, et al. Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2. The Lancet Microbe. 2025;6(11):101165. doi:10.1016/j.lanmic.2025.101165
BibTeX
@article{Zhang2025,
author = {Zhang, Lu and Kempf, Amy and Nehlmeier, Inga and Chen, Nianzhen and Stankov, Metodi V and Happle, Christine and Dopfer-Jablonka, Alexandra and Behrens, Georg M N and Schulz, Sebastian R and Jäck, Hans-Martin and Pöhlmann, Stefan and Hoffmann, Markus},
title = {Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2},
journal = {The Lancet Microbe},
year = {2025},
volume = {6},
number = {11},
pages = {101165},
doi = {10.1016/j.lanmic.2025.101165}
}
EUVIMED